BCL2 and B-cell chronic lymphocytic leukemia: On the other hand, ABT‐199 is most effective in leukemia which is more often BCL2‐dependent, such as B‐cell‐derived chronic lymphocytic leukemia (CLL) 91 and some types of acute myeloid leukemias 92.